Macular Degeneration Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The macular degeneration treatment market is segmented by Type (Dry age-related macular degeneration, Wet age-related macular degeneration), Stage of Disease, Route of Administration and Geography

Market Snapshot

Study Period:

2018 - 2026

Base Year:


Fastest Growing Market:

Asia Pacific

Largest Market:

North America


7.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The macular degeneration treatment market was projected to grow with a CAGR of nearly 7.4% during the forecast period. The major factors attributing to the growth of the macular degeneration treatment market are, rise in the incidence of retinal disorders, increasing the geriatric population in the majority of the developing nations. 

According to the data published in the European Society of Retina Specialists (EURETINA) an estimated number of 33.6 million persons over the age of 60 years in Europe are currently affected by AMD. As per the statistics, the increasing number of individuals with retinal disorders is directly proportional to the market growth. Furthermore, the increasing research and development investments, rising approvals for the new drugs of the treatment are other major factors for the market growth. However, the increasing use of off-label drugs and lack of awareness regarding the disease are the major restraints to the growth of the market.

Scope of the Report

As per the scope of the report, macular degeneration is a retinal disorder affecting older people. Early stages of the disease, (early and intermediate AMD) are generally asymptomatic, which gradually make progress to late stages of the disease, which can cause severe visual loss.

By Type
Dry Age related macular degeneration
Wet Age-related macular degeneration
By Stage of Disease
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Route of Administration
Intravenous route
Intravitreal route
By Sales Channel
Ambulatory surgical centers
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Wet AMD has been Accounted for the Majority of Share in the Market

Wet macular degeneration is an initiation of atypical growth of blood vessels beneath the retina, these overgrown blood vessels drip blood which impedes clarity of central vision heading to macular degeneration.

The rising number of geriatric population all over the world is creating the high-level demand in wet macular degeneration market. According to the World Health Organization (WHO) report, the percentage of old people (above 60 years) is expected to become 21.1% by the year 2050. The total number of old age people all over the world is probable to reach 2 billion in 2050. All these statistics represent the high demand for the products for the treatment of wet macular degeneration globally in coming future. The technological advancements in the diagnosis of macular degeneration and appropriate reimbursement circumstances are driving the growth of the market.

Macular Degeneration Treatment

To understand key trends, Download Sample Report

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall macular degeneration treatment market, throughout the forecast period. The market growth is because of more awareness and a greater proportion of total income spent on healthcare compared to other economies. 

According to BrightFocus Foundation, in 2016, 11 million people in the United States have certain forms of age-related macular degeneration. This number is estimated to reach nearly 22 million by 2050. The growing patient pool and the increasing geriatric population who are more prone to retinal diseases are the two major factors driving the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Macular Degeneration Treatment Market 2

To understand geography trends, Download Sample Report

Competitive Landscape

The macular degeneration treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., and Pfizer Inc.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Incidence of Retinal Disorders

      2. 4.2.2 Upsurge in Geriatric Population

      3. 4.2.3 Increase in Research and Development Investments

    3. 4.3 Market Restraints

      1. 4.3.1 Increasing Use of Off-label Drugs

      2. 4.3.2 Lack of Awareness regarding AMD

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Dry Age related macular degeneration

      2. 5.1.2 Wet Age-related macular degeneration

    2. 5.2 By Stage of Disease

      1. 5.2.1 Early-stage AMD

      2. 5.2.2 Intermediate AMD

      3. 5.2.3 Late-stage AMD

    3. 5.3 By Route of Administration

      1. 5.3.1 Intravenous route

      2. 5.3.2 Intravitreal route

    4. 5.4 By Sales Channel

      1. 5.4.1 Ambulatory surgical centers

      2. 5.4.2 Hospitals

      3. 5.4.3 Others

    5. 5.5 Geography

      1. 5.5.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.5.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.5.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.5.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 F. Hoffmann-La Roche AG.

      2. 6.1.2 Novartis AG

      3. 6.1.3 Bausch Health Companies Inc.

      4. 6.1.4 Pfizer Inc.

      5. 6.1.5 Panoptica

      6. 6.1.6 Aerie Pharmaceutical Inc.

      7. 6.1.7 REGENXBIO Inc.

      8. 6.1.8 Ellex

      9. 6.1.9 Regeneron Pharmaceuticals, Inc.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Macular Degeneration Treatment Market market is studied from 2018 - 2026.

The Macular Degeneration Treatment Market is growing at a CAGR of 7.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Regeneron
  • Bausch Health Companies Inc.
  • Pfizer Inc.

Are the major companies operating in Macular Degeneration Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!